Clinical-stage precision oncology

Precision oncology, accelerated.

Tethra Biosciences is developing plogosertib (THT-140), a differentiated oral PLK1 inhibitor for cancers where current treatment options remain limited.

Our Science View Pipeline
1
Clinical-stage program
3
Indication tracks
Global
Patent estate
Ph 1/2
Active development

Who we are

A focused team advancing a high-conviction asset.

Tethra Biosciences is a clinical-stage precision oncology company built around a single, differentiated asset. We combine experienced oncology drug development with a capital-efficient approach — advancing toward value-driving milestones in cancers where current therapies fall short.

Our asset

plogosertib (THT-140)

A next-generation, differentiated oral PLK1 inhibitor in active Phase 1/2 development across oncology and hematology.

Pipeline

Three indication tracks across one program.

plogosertib (THT-140) — biomarker-defined development across oncology and hematology.

Biomarker-defined

Solid Tumors

Biomarker-defined

Lymphoma

Biomarker-defined

Acute Myeloid Leukemia (AML)

View pipeline

Why Tethra

Built for capital-efficient inflection.

Differentiated chemistry

plogosertib is a next-generation PLK1 inhibitor with an optimized profile for cancer indications.

Disciplined development

Three indication tracks built around a single chemistry; resource concentration and clear go / no-go gates.

Experienced operators

Oncology drug developers, regulatory leaders, and clinical operators across hematology and solid tumors.

plogosertib (THT-140) is investigational and has not been approved by any health authority. Forward-looking statements reflect current expectations and involve risks and uncertainties.